首页> 美国卫生研究院文献>Case Reports in Anesthesiology >Change of Anesthesia Management for a Patient Undergoing CABG by an Incidental Finding of a Genetic Variant Associated with Malignant Hyperthermia
【2h】

Change of Anesthesia Management for a Patient Undergoing CABG by an Incidental Finding of a Genetic Variant Associated with Malignant Hyperthermia

机译:偶然发现伴有恶性高热的遗传变异对接受CABG的患者进行麻醉管理的变化

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Malignant hyperthermia (MH) is a rare life-threatening hypermetabolic muscular disorder with a high mortality rate. Three genes, RYR1, CACNA1S, and STAC3, have been associated with MH susceptibility. Multiple genetic variants have been identified in these three genes. Some of those variants were pathogenic, but many others are yet to be tested. Such uncertainty can make it challenging for anesthesia providers as there is currently no anesthesia guideline for each genetic variant in patients who have neither clinical nor family history of MH. With the increasing popularity of whole exome sequencing, anesthesia providers will likely face such challenges more often as many patients may have genetic variations of unknown clinical significance in their RYR1, CACNA1S, or STAC3 genes. Here we describe change of anesthesia management for a patient who had an incidental finding of a genetic variant in RYR1 gene undergoing an elective coronary artery bypass surgery.
机译:恶性高热(MH)是一种罕见的威胁生命的高代谢性肌肉疾病,死亡率高。 MHR易感性与RYR1,CACNA1S和STAC3这三个基因有关。在这三个基因中已鉴定出多种遗传变异。这些变体中有一些是致病的,但还有许多尚待测试。这种不确定性可能给麻醉提供者带来挑战,因为对于没有临床或家族史的MH患者,目前尚无针对每种遗传变异的麻醉指南。随着全外显子组测序的日益普及,麻醉提供者将可能更经常面临此类挑战,因为许多患者的RYR1,CACNA1S或STAC3基因可能具有未知的临床意义的遗传变异。在这里,我们描述了对一名接受择期冠状动脉搭桥手术的RYR1基因遗传变异偶然发现的患者进行麻醉管理的变化。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号